Cargando…

Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides

Oligonucleotide analogs have provided novel therapeutics targeting various disorders. However, their poor cellular uptake remains a major obstacle for their clinical development. Negatively charged oligonucleotides, such as 2′-O-Methyl RNA and locked nucleic acids have in recent years been delivered...

Descripción completa

Detalles Bibliográficos
Autores principales: Järver, Peter, Zaghloul, Eman M., Arzumanov, Andrey A., Saleh, Amer F., McClorey, Graham, Hammond, Suzan M., Hällbrink, Mattias, Langel, Ülo, Smith, C.I. Edvard, Wood, Matthew J.A., Gait, Michael J., EL Andaloussi, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376484/
https://www.ncbi.nlm.nih.gov/pubmed/25594433
http://dx.doi.org/10.1089/nat.2014.0511
_version_ 1782363743398658048
author Järver, Peter
Zaghloul, Eman M.
Arzumanov, Andrey A.
Saleh, Amer F.
McClorey, Graham
Hammond, Suzan M.
Hällbrink, Mattias
Langel, Ülo
Smith, C.I. Edvard
Wood, Matthew J.A.
Gait, Michael J.
EL Andaloussi, Samir
author_facet Järver, Peter
Zaghloul, Eman M.
Arzumanov, Andrey A.
Saleh, Amer F.
McClorey, Graham
Hammond, Suzan M.
Hällbrink, Mattias
Langel, Ülo
Smith, C.I. Edvard
Wood, Matthew J.A.
Gait, Michael J.
EL Andaloussi, Samir
author_sort Järver, Peter
collection PubMed
description Oligonucleotide analogs have provided novel therapeutics targeting various disorders. However, their poor cellular uptake remains a major obstacle for their clinical development. Negatively charged oligonucleotides, such as 2′-O-Methyl RNA and locked nucleic acids have in recent years been delivered successfully into cells through complex formation with cationic polymers, peptides, liposomes, or similar nanoparticle delivery systems. However, due to the lack of electrostatic interactions, this promising delivery method has been unsuccessful to date using charge-neutral oligonucleotide analogs. We show here that lipid-functionalized cell-penetrating peptides can be efficiently exploited for cellular transfection of the charge-neutral oligonucleotide analog phosphorodiamidate morpholino. The lipopeptides form complexes with splice-switching phosphorodiamidate morpholino oligonucleotide and can be delivered into clinically relevant cell lines that are otherwise difficult to transfect while retaining biological activity. To our knowledge, this is the first study to show delivery through complex formation of biologically active charge-neutral oligonucleotides by cationic peptides.
format Online
Article
Text
id pubmed-4376484
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-43764842015-05-13 Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides Järver, Peter Zaghloul, Eman M. Arzumanov, Andrey A. Saleh, Amer F. McClorey, Graham Hammond, Suzan M. Hällbrink, Mattias Langel, Ülo Smith, C.I. Edvard Wood, Matthew J.A. Gait, Michael J. EL Andaloussi, Samir Nucleic Acid Ther Original Articles Oligonucleotide analogs have provided novel therapeutics targeting various disorders. However, their poor cellular uptake remains a major obstacle for their clinical development. Negatively charged oligonucleotides, such as 2′-O-Methyl RNA and locked nucleic acids have in recent years been delivered successfully into cells through complex formation with cationic polymers, peptides, liposomes, or similar nanoparticle delivery systems. However, due to the lack of electrostatic interactions, this promising delivery method has been unsuccessful to date using charge-neutral oligonucleotide analogs. We show here that lipid-functionalized cell-penetrating peptides can be efficiently exploited for cellular transfection of the charge-neutral oligonucleotide analog phosphorodiamidate morpholino. The lipopeptides form complexes with splice-switching phosphorodiamidate morpholino oligonucleotide and can be delivered into clinically relevant cell lines that are otherwise difficult to transfect while retaining biological activity. To our knowledge, this is the first study to show delivery through complex formation of biologically active charge-neutral oligonucleotides by cationic peptides. Mary Ann Liebert, Inc. 2015-04-01 /pmc/articles/PMC4376484/ /pubmed/25594433 http://dx.doi.org/10.1089/nat.2014.0511 Text en © Peter Jäver et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Articles
Järver, Peter
Zaghloul, Eman M.
Arzumanov, Andrey A.
Saleh, Amer F.
McClorey, Graham
Hammond, Suzan M.
Hällbrink, Mattias
Langel, Ülo
Smith, C.I. Edvard
Wood, Matthew J.A.
Gait, Michael J.
EL Andaloussi, Samir
Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
title Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
title_full Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
title_fullStr Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
title_full_unstemmed Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
title_short Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
title_sort peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376484/
https://www.ncbi.nlm.nih.gov/pubmed/25594433
http://dx.doi.org/10.1089/nat.2014.0511
work_keys_str_mv AT jarverpeter peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT zaghloulemanm peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT arzumanovandreya peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT salehamerf peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT mccloreygraham peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT hammondsuzanm peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT hallbrinkmattias peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT langelulo peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT smithciedvard peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT woodmatthewja peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT gaitmichaelj peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides
AT elandaloussisamir peptidenanoparticledeliveryofchargeneutralspliceswitchingmorpholinooligonucleotides